References
- BrennerSMatzHImprovement in androgenetic alopecia in 53–76-year-old men using oral finasterideInt J Dermatol1999381292893010632776
- HoffmannRFinasteride is the main inhibitor of 5α-reductase activity in microdissected dermal papillae of human hair folliclesArch Dermatol Res19992912–310010310195397
- WhitingDAdvances in the treatment of male androgenetic alopecia: a brief review of finasteride studiesEur J Dermatology2001114332334
- KaufmanKFinasteride, 1 mg (Propecia), is the optimal dose for the treatment of men with male pattern hair lossArch Dermatol1999135898999010456354
- D’AmicoARoehrbornCEffect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trialLancet Oncol200781212517196507
- PriceVMenefeeESanchezMChanges in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three-and 4-year resultsJ Am Acad Dermatol2006551717416781295
- RathnayakeDSinclairRMale androgenetic alopeciaExpert Opin Pharmacother20101181295130420426708
- US Food and Drug AdministrationDrug Approval Package Proscar (Finasteride) Tablets Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/020180_s027_ProscarTOC.cfmAccessed December 14, 2017
- HirshburgJMKelseyPATherrienCAGavinoACReichenbergJSAdverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): a systematic reviewJ Clin Aesthet Dermatol2016975662
- Carreño-OrellanaNMoll-ManzurCCarrasco-ZuberJEÁlvarez-VélizSBerroeta-MaurizianoDPorras-KusmanicNEfectos adversos de finasteride: mitos y realidades. Una revisión actualizada [Finasteride adverse effects: An update]Rev Med Chil20161441215841590 Spanish28393993
- CarusoDAbbiatiFGiattiSPatients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasmaJ steroid Biochem Mol Biol2015146747924717976
- AhmedOAAAfounaMIEl-SayKMAbdel-NaimABKhedrABanjarZMOptimization of self-nanoemulsifying systems for the enhancement of in vivo hypoglycemic efficacy of glimepiride transdermal patchesExpert Opin Drug Deliv20141171005101324702435
- CaonTPortoLGranadaAChitosan-decorated polystyrene-b-poly (acrylic acid) polymersomes as novel carriers for topical delivery of finasterideEur J Pharm Sci20145216517224262075
- CaseriniMRadicioniMLeurattiCAnnoniOPalmieriRA novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteersInt J Clin Pharmacol Ther2014521084284925074865
- MaestrelliFGonzález-RodríguezMEffect of preparation technique on the properties of liposomes encapsulating ketoprofen–cyclodextrin complexes aimed for transdermal deliveryInt J Pharm20063121–2536016469460
- MezeiMGulasekharamVLiposomes – a selective drug delivery system for the topical route of administration. Lotion dosage formLife Sci19802618147314776893068
- MezeiMGulasekharamVLiposomes – a selective drug delivery system for the topical route of administration: gel dosage formJ Pharm Pharmacol19823474734746126554
- RajanRJoseSMukundVTransferosomes-A vesicular transdermal delivery system for enhanced drug permeationJ Adv Pharm Technol Res20112313814322171309
- Badr-EldinSMAhmedOAAOptimized nano-transfersomal films for enhanced sildenafil citrate transdermal delivery: ex vivo and in vivo evaluationDrug Des Devel Ther20161013231333
- CevcGBlumeGNew, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, TransfersomesBiochim Biophys Acta20011514219120511557020
- BensonHATransfersomes for transdermal drug deliveryExpert Opin Drug Deliv20063672773717076595
- BragagniMMenniniNMaestrelliFCirriMMuraPComparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxibDrug Deliv201219735436123043648
- MahmoodSTaherMMandalUExperimental design and optimization of raloxifene hydrochloride loaded nanotransfersomes for transdermal applicationInt J Nanomedicine201494331434625246789
- ChoiMMaibachHElastic vesicles as topical/transdermal drug delivery systemsInt J Cosmet Sci200527421122118492190
- NtimenouVFahrAElastic vesicles for transdermal drug delivery of hydrophilic drugs: a comparison of important physicochemical characteristics of different vesicle typesJ Biomed Nanotechnol20128461362322852471
- El-NabarawiMBendasEEl RehemRAMYTransdermal drug delivery of paroxetine through lipid-vesicular formulation to augment its bioavailabilityInt J Pharm20134431–230731723337629
- ShammaRNElsayedITransfersomal lyophilized gel of buspirone HCl: formulation, evaluation and statistical optimizationJ Liposome Res201323324425423713516
- AhmedOAHusseinAKMadyFMOptimisation of microstructured biodegradable finasteride formulation for depot parenteral applicationJ Microencapsul201633322923826886073
- AhmedOAAAhmedTAAbdel-NaimABKhedrABanjarZMAfounaMIEnhancement of in vitro skin transport and in vivo hypoglycemic efficacy of glimepiride transdermal patchesTrop J Pharm Res201413812071213
- HiguchiTMechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matricesJ Pharm Sci196352121145114914088963
- CostaPSousa LoboJMModeling and comparison of dissolution profilesEur J Pharm Sci200113212313311297896
- El ZaafaranyGGMAwadGGASHolayelSSMMortadaNDNRole of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin deliveryInt J Pharm20103971–216417220599487
- BensonHElastic liposomes for topical and transdermal drug deliveryCurr Drug Deliv20096321722619604135